{
    "abstract": "To compare the efficacy and safety of the Ankura Plus and Castor stents in Stanford type B aortic dissection (TBAD) with an insufficient proximal anchoring area.\nBetween January 2020 and October 2022, 54 patients with TBAD were enrolled, including 16 patients with Ankura Plus stents and 38 patients with Castor stents. Data from the 2 stents were retrospectively analyzed.\nThe surgical success rate for both stents was 100%, and no endoleaks or deaths occurred during hospitalization. The Ankura Plus stent group had a longer surgery time than the Castor stent group (122.6\u00a0\u00b1\u00a05.1 vs. 103.7\u00a0\u00b1\u00a010.0, P < 0.001). After an average follow-up of 12\u00a0months, the patency rates of the main and branch stents were 100% in both groups. The diameter of the true lumen (TL) was significantly increased, the diameter of the false lumen (FL) was reduced, and there was no statistically significant difference in the probability of complete thrombosis of the FL (68.8% vs. 67.6%, P\u00a0=\u00a00.993). There were no significant differences in the incidences of renal failure (6.3% vs. 8.1%, P\u00a0=\u00a00.814), stroke (6.3% vs. 2.7%, P\u00a0=\u00a00.520), or endoleaks (6.3% vs. 10.5%, P\u00a0=\u00a00.621) between the Ankura Plus and Castor stent groups. One patient in the Castor stent group underwent reintervention because of a type I endoleak 3\u00a0months after surgery. One patient in the Ankura Plus stent group had an additional covered stent placed after 1\u00a0month due to distal TL stenosis of the main stent. One patient in the Castor stent group died of renal failure 4\u00a0months after surgery.\nBoth the Ankura Plus and Castor stents are feasible, safe, and effective in the treatment of TBAD with an insufficient proximal anchoring area. Additional long-term studies are required to evaluate the robustness and applicability of Ankura Plus stents.",
    "authors": [
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China.",
            "firstname": "Boyu",
            "initials": "B",
            "lastname": "Liu"
        },
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, the First Hospital of Hebei Medical University, Shijiazhuang, China.",
            "firstname": "Like",
            "initials": "L",
            "lastname": "Zhang"
        },
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, the First Hospital of Hebei Medical University, Shijiazhuang, China.",
            "firstname": "Peng",
            "initials": "P",
            "lastname": "Liu"
        },
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, the First Hospital of Hebei Medical University, Shijiazhuang, China.",
            "firstname": "Zibin",
            "initials": "Z",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China.",
            "firstname": "Boyu",
            "initials": "B",
            "lastname": "Wang"
        },
        {
            "affiliation": "Department of Vascular Surgery, the First Hospital of Hebei Medical University, Shijiazhuang, China; Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, the First Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: drleizhang@163.com.",
            "firstname": "Lei",
            "initials": "L",
            "lastname": "Zhang"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2024 The Authors. Published by Elsevier Inc. All rights reserved.",
    "doi": "10.1016/j.avsg.2024.07.114",
    "journal": "Annals of vascular surgery",
    "keywords": [],
    "methods": null,
    "publication_date": "2024-09-29",
    "pubmed_id": "39341554",
    "results": "The surgical success rate for both stents was 100%, and no endoleaks or deaths occurred during hospitalization. The Ankura Plus stent group had a longer surgery time than the Castor stent group (122.6\u00a0\u00b1\u00a05.1 vs. 103.7\u00a0\u00b1\u00a010.0, P < 0.001). After an average follow-up of 12\u00a0months, the patency rates of the main and branch stents were 100% in both groups. The diameter of the true lumen (TL) was significantly increased, the diameter of the false lumen (FL) was reduced, and there was no statistically significant difference in the probability of complete thrombosis of the FL (68.8% vs. 67.6%, P\u00a0=\u00a00.993). There were no significant differences in the incidences of renal failure (6.3% vs. 8.1%, P\u00a0=\u00a00.814), stroke (6.3% vs. 2.7%, P\u00a0=\u00a00.520), or endoleaks (6.3% vs. 10.5%, P\u00a0=\u00a00.621) between the Ankura Plus and Castor stent groups. One patient in the Castor stent group underwent reintervention because of a type I endoleak 3\u00a0months after surgery. One patient in the Ankura Plus stent group had an additional covered stent placed after 1\u00a0month due to distal TL stenosis of the main stent. One patient in the Castor stent group died of renal failure 4\u00a0months after surgery.",
    "title": "Comparison of the Novel Ankura Plus Stent and Castor Stent for the Treatment of Stanford Type B Aortic Dissection with an Insufficient Proximal Anchoring Area.",
    "xml": "<Element 'PubmedArticle' at 0x788506410180>"
}